Clinical Trials Sponsored by Sonic Incytes

Total 420 results

Incyte Corporation

Completed

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Incyte Corporation

Withdrawn

A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris

Pemphigus Vulgaris
Incyte Corporation

Completed

Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors

Pancreatic Cancer | Solid Tumors

United States
Incyte Corporation

Terminated

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Melanoma

United States
Incyte Corporation

Completed

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Puerto Rico
Incyte Corporation

Terminated

Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs (DECLARE)

HIV Infections | Human Immunodeficiency Virus

United States, Puerto Rico
Incyte Corporation

Completed

Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics

Type 2 Diabetes

United States, Puerto Rico
Incyte Corporation

Completed

Study of Ruxolitinib in Pancreatic Cancer Patients (RECAP)

Pancreatic Cancer

United States
Incyte Corporation

Terminated

Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer

Breast Cancer

India
Incyte Corporation

Completed

A Dose-escalation Study in Subjects With Advanced Malignancies

Solid Tumors and Hematologic Malignancy

United States
Incyte Corporation

Terminated

INCB047986 in Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Incyte Corporation

Completed

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Myelofibrosis

United States
Incyte Corporation

Completed

A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes

Obesity | Insulin Resistance

United States
Incyte Biosciences Japan GK

Recruiting

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (J-MIND)

Diffuse Large B-cell Lymphoma | Non Hodgkins Lymphoma

Japan
Incyte Biosciences International Sàrl

Completed

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Advanced Malignancies

United States
Incyte Biosciences International Sàrl

Terminated

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Metastatic Cancer | Advanced Malignancies

United States
Incyte Biosciences International Sàrl

Completed

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Cervical Cancer | Hepatocellular Carcinoma | Esophageal Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer (NSCLC) | Urothelial Carcinoma | Merkel Cell Carcinoma | Diffuse Large B-cell Lymphoma | Triple-negative Breast Cancer | Renal Cell Carcinoma (RCC) | Small Cell Lung Cancer (SCLC) | Squamous... and other conditions

United States
Incyte Biosciences International Sàrl

Withdrawn

A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

BCR-ABL Positive Acute Lymphoblastic Leukemia

Germany, France, Czechia
Incyte Corporation

Not yet recruiting

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

Hematologic Malignancies
Incyte Corporation

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Chronic Graft-versus-host-disease
Incyte Corporation

Recruiting

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa (STOP-HS LTE)

Hidradenitis Suppurativa (HS)

United States, Austria, Belgium, Canada, Germany, Poland, Spain, Australia, Denmark, France, United Kingdom, Japan, Bulgaria, Netherlands, Czechia, Greece, Italy
Incyte Corporation

Recruiting

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

NonSegmental Vitiligo

Germany, United States, Poland, Italy, Canada, France, Bulgaria, Hungary, United Kingdom
Incyte Corporation

Recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (LIMBER)

Myeloproliferative Neoplasms

Spain, Japan, France, Italy, Germany, Australia, United Kingdom, Denmark, Canada
Incyte Corporation

Recruiting

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease (THRIVE)

cGVHD

United States
Incyte Corporation

Recruiting

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Advanced Solid Tumor

Brazil, Georgia, Greece, Turkey, Mexico, Romania, South Africa, Hungary, New Zealand, China
Incyte Corporation

Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Advanced Solid Tumors | Solid Tumors | Metastatic Solid Tumors

United States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
Incyte Corporation

Recruiting

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. (MORPHEUS)

Atopic Dermatitis

United States
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302)

Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma

United States, Canada, Belgium, France, Germany, Italy, China, Spain, Japan, United Kingdom, Netherlands, Switzerland, Austria, Denmark, Finland, Ireland, Israel, Norway, Sweden
Incyte Corporation

Active, not recruiting

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Spain, France, Italy, Belgium, Germany, Austria
Incyte Corporation

Active, not recruiting

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

Squamous Cell Carcinoma of the Anal Canal

United States, Italy, Spain, United Kingdom, Australia, France, Germany, Sweden, Japan, Norway, Belgium, Denmark, Puerto Rico
Incyte Corporation

Active, not recruiting

Study of INCA 0186 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Gastrointestinal (GI) Malignancies

United States, Netherlands, Spain, United Kingdom, Belgium, Austria
Incyte Corporation

Active, not recruiting

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Advanced Solid Tumors

United States, Sweden, Netherlands, Norway, Denmark
Incyte Corporation

Completed

A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

Healthy Participants

United States
Incyte Corporation

Terminated

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (PATHWAY)

Warm Autoimmune Hemolytic Anemia (wAIHA)

Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
Incyte Corporation

Active, not recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
Incyte Corporation

Terminated

Study of INCB086550 in Select Solid Tumors

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Urothelial Cancer

Korea, Republic of, Bulgaria, Hungary, Taiwan, Ukraine
Incyte Corporation

Completed

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

NonSegmental Vitiligo

United States, Canada
Incyte Corporation

Active, not recruiting

Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

Atopic Dermatitis (AD)

Canada, United States, Poland
Incyte Corporation

Completed

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Kidney Diseases | Renal Insufficiency

United States, Germany
Incyte Corporation

Completed

Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States, Canada
Incyte Corporation

Available

Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)

Chronic Graft Vs. Host Disease
Incyte Corporation

Active, not recruiting

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

Follicular Lymphoma | Marginal Zone Lymphoma

Finland, United States, Spain, Korea, Republic of, Canada, Israel, Turkey, United Kingdom, Netherlands, Greece, Italy, France, Taiwan, Germany, Belgium, Japan, Czechia, Switzerland, Ireland, Poland, Ukraine, Australia, Denmark, Hungary, Swede... and more
Incyte Corporation

Completed

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

Kidney Diseases | Renal Insufficiency

United States, Germany
Incyte Corporation

Terminated

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma (Optimus)

Urothelial Carcinoma

United States, France, Italy
Incyte Corporation

Completed

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

Vitiligo

United States, Canada
Incyte Corporation

Terminated

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Chronic Graft-versus-host Disease

United States, Spain, France, Canada, Israel, United Kingdom, Germany, Italy, Denmark, Sweden, Finland, Belgium, Poland, Greece, Austria, Switzerland
Incyte Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus

Lichen Sclerosus

United States, Canada
Incyte Corporation

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)

Glioblastoma | Adult-type Diffuse Gliomas

United States, Spain, Italy, United Kingdom, Germany, Japan, France, Netherlands, Denmark
Incyte Corporation

Completed

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Ovarian Cancer | Endometrial Cancer | Solid Tumors | Biliary Tract Cancer (BTC) | Colorectal Cancer (CRC) | Gastroesophageal Cancer (GC)

United Kingdom, United States, Belgium
Incyte Corporation

Completed

A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors

Solid Tumors

United States, Italy, United Kingdom, France, Belgium

Clinical Trials Sponsored by Sonic Incytes

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations